Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study

Objective To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.Methods FUTURE 5 was a randomised, double-blind, placebo-c...

Full description

Bibliographic Details
Main Authors: Philip J Mease, Dafna D Gladman, Laura C Coates, Sandra Navarra, Corine Gaillez, Weibin Bao
Format: Article
Language:English
Published: BMJ Publishing Group 2023-04-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/2/e002939.full

Internet

https://rmdopen.bmj.com/content/9/2/e002939.full

Similar Items